Recursion Pharmaceuticals' (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials

Yahoo FinanceDec 12 21:55

Hold Rating for Recursion Pharmaceuticals Amid Early Efficacy Signals and Financial Concerns

TipRanksDec 12 15:07

Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers

Yahoo FinanceDec 12 00:48

Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11

Futu NewsDec 11 22:33 · Ratings

Promising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy Rating

TipRanksDec 11 21:35 · Ratings

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

BenzingaDec 11 21:26 · Ratings